Rapidly progressive glomerulonephritis: current and evolving treatment strategies.
Rapidly progressive glomerulonephritis (RPGN) must be diagnosed and treated quickly to prevent irreversible organ injury. The commonest cause of RPGN is anti-neutrophil cytoplasm antibody (ANCA) associated small vessel vasculitis, and the most severe is anti-glomerular basement membrane (GBM) antibody disease. In this review we address pathogenesis, diagnosis, treatment and outcome in these two entities, with emphasis on novel therapies.
Little
Mark A
MA
Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Pusey
Charles D
CD
D019867:Anti-Glomerular Basement Membrane Disease / Q000628:therapy; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000032:analysis; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D003937:Diagnosis, Differential; D018450:Disease Progression; D005921:Glomerulonephritis / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D010951:Plasma Exchange
D019268:Antibodies, Antineutrophil Cytoplasmic; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008775:Methylprednisolone